- Companies
- Grüns
Grüns Acquisition, Valuation, Funding & Investors
Grüns was acquired by Unilever for $1.2B in April 2026, a 4.0x multiple on $300M of revenue.
Grüns revenue at acquisition
$300M
Last twelve months · Apr 2026
Grüns revenue multiple at acquisition
4.0x
EV/Revenue · Apr 2026
Cumulative funding Grüns raised
$10M
across 1 funding round
About Grüns
Grüns is a company producing health supplements as gummy snacks. It formulates nutrition products with vitamins, probiotics, and superfoods targeted at daily wellness for adults and children.
Founded
2023
HQ
Website
Status
Acquired
Customer focus
B2C
Revenue model
Product sales
Revenue
$300M (Apr 2026)
Valuation
$450M (Apr 2025)
Grüns Acquisition
Grüns was acquired by Unilever for $1.2B on 8 April 2026.
The acquisition price implies a 4.0x revenue multiple on $300M of revenue.
Before the acquisition Grüns had raised $10M across 1 funding round.
| Acquirer | Date | Type | Price | EV/Revenue |
|---|---|---|---|---|
| 8 Apr 2026 | Strategic M&A | $1.2B | 4.0x |
Grüns Valuation
Grüns is currently valued at $450M, based on its undisclosed-stage round in April 2025.
Grüns valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Apr 2025 | Undisclosed stage | $450M |
Grüns Funding History
Grüns has raised a total of $10M across 1 funding round.
Grüns funding rounds
| Date | Stage | Raised | Valuation | Deal Summary |
|---|---|---|---|---|
| Apr 2025 | Undisclosed stage | $10M | $450M | Grüns is a gummy supplement company offering functional gummy bears with ingredients like powdered fruits and vegetables, vitamins, probiotics, and nootropics for nutritional support, including kids' versions and cognitive products. The company launched in 2023, sells DTC and in over 5,000 retail doors including Sprouts, Target, and Walmart, and ships 4 million gummies per day. It has expanded product lines with new SKUs and plans international growth into Asia and Australia. In April-May 2025, Grüns raised $35 million in a Series B round led by Headline, with participation from Plus Capital, Sugar Capital, and celebrities like Anna Kendrick and Shaun White, achieving a post-money valuation of $500 million USD. This followed prior funding including $18 million in 2024 and brought total funding to over $50 million across multiple rounds. The capital supports scaling distribution, launching new products like one per quarter starting August 2025, retail expansion, TV advertising, sports partnerships such as with Gotham FC, and international markets. Grüns demonstrated strong traction with nine-figure annual recurring revenue at the time of the Series B, rapid retail penetration in major chains within two years, and appeal to Gen Z and millennials preferring gummies over pills for needs like gut health, energy, and immunity. The brand positions in the growing gummy supplement market, which comprises 23% of supplement sales, amid a boom in supplement startups. |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialGrüns Competitors
Grüns competitors include listed companies like Jamieson Wellness, Procter & Gamble Health, Mega Lifesciences and Zydus Wellness, and private ones like L&P Cosmetic and Grupo Cimed.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $589M | $95M | $1.4B | 2.6x | ||
| Publicly listed | $144M | $48M | $941M | 6.0x | ||
| Publicly listed | $425M | $82M | $936M | 1.9x | ||
| Publicly listed | $411M | $49M | $1.8B | 4.5x | ||
| Private | - | - | $1.1B | - | ||
| Private | - | - | $1.4B | - |
Grüns Public Comps
Grüns is no longer listed, but its public comps include Edgewell, BioGaia, Chicmax Cosmetic, Jamieson Wellness, Intercos, Cosmecca Korea, Procter & Gamble Health, Mega Lifesciences, T Hasegawa and Sarantis Group.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $2.2B | $186M | 1.0x | 1.1x | 11.5x | 8.5x | |||
| $157M | $44M | 6.8x | 6.2x | 23.9x | 20.4x | |||
| $1.4B | $235M | 0.8x | 0.8x | 4.5x | 7.3x | |||
| $589M | $95M | 2.9x | 2.6x | 17.8x | 13.5x | |||
| $1.2B | $159M | 1.2x | 1.2x | 9.4x | 8.0x | |||
| $467M | $71M | 2.5x | 2.1x | 16.5x | 12.9x | |||
| $144M | $48M | 6.4x | 6.0x | 19.1x | 18.3x | |||
| $425M | $82M | 2.0x | 1.9x | 10.2x | 8.4x | |||
This data is available for Pro users. Sign up to see all Grüns competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Grüns
| When was Grüns founded? | Grüns was founded in 2023. |
| Where is Grüns headquartered? | Grüns is headquartered in Portland, OR, United States. |
| Is Grüns publicly listed? | No, Grüns was acquired by Unilever in April 2026. |
| Who acquired Grüns? | Grüns was acquired by Unilever in April 2026. |
| How much was Grüns acquired for? | Grüns was acquired for $1.2B in April 2026, a 4.0x revenue multiple. |
| What is Grüns' valuation? | Grüns was last valued at $450M in its undisclosed-stage round in April 2025. |
| How much funding has Grüns raised? | Grüns has raised $10M across 1 funding round. |
| What was Grüns' last funding round? | Grüns' last funding round was a $10M undisclosed-stage round in April 2025. |
| Which companies are comparable to Grüns? | Companies comparable to Grüns include Jamieson Wellness, Procter & Gamble Health, Mega Lifesciences, Zydus Wellness, L&P Cosmetic and Grupo Cimed. |
See companies similar to Grüns
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




